Uncategorized The PD-1/PD-L1 Race in China

The PD-1/PD-L1 Race in China

Since its approval as the first PD-1/PD-L1 inhibitor, on September 4, 2014, Keytruda has stood on the top of the heap and dominated attention across the spectrum of industry watchers. At present, the competition in this field is especially fierce. All five PD-1/PD-L1 inhibitors on the market are actively expanding their territories and rapidly pushing …

Read Article Read More

Uncategorized The biosimilar race in China

The biosimilar race in China

Across the globe, many countries have pegged big hopes on biosimilars. The situation is no different in China.  In the face of the supportive pharmaceutical industry policies, the biosimilar drug development in China is riding on an upward trend. However, compared to the advanced US and European market, China still has plenty of room to …

Read Article Read More

Uncategorized China’s CAR-T Therapy Race

China’s CAR-T Therapy Race

On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR-T cell self-reinfusion preparation from Nanjing Legend Biotech, marking the first cellular therapy to officially enter the clinical trial stage in China. LCAR-B38M is targeted at B-cell maturation antigen (BCMA), a member of TNF receptor family and also an extremely …

Read Article Read More

Uncategorized 8 major events in the genetics field in 2017

8 major events in the genetics field in 2017

In 2017, gene technology has achieved extensive advancements. In this article, I am going to discuss 8 major events happened this year. 1. The first human genetic modification therapy was officially launched Brian Madeux, suffering from a rare condition called Hunter Syndrome, has all eyes fixed on him in 2017. He is the first patient …

Read Article Read More

Uncategorized Which business tycoons are entering the healthcare industry in China this year?

Which business tycoons are entering the healthcare industry in China this year?

In the recent years, the healthcare industry has been gaining steam across the spectrum of various industries, from internet to real estate, to high tech and traditional manufacturing, etc. A slew of business giants is marching into this field, and this is especially true in 2017. Several famous new faces have joined the rank. Wanda …

Read Article Read More

Uncategorized Who will be the next Illumina? A complete overview of the third-generation gene sequencing market in China

Who will be the next Illumina? A complete overview of the third-generation gene sequencing market in China

Next Generation Sequencing (NGS) has been standing on the top of the heap in the past few years. Riding on this steady upward trend, a slew of biotech companies has achieved great successes, such as Illumina and Beijing Genomics Institute. Nowadays, a new technology called the third-generation gene sequencing is gradually gaining attention and began …

Read Article Read More

Uncategorized Why Eli Lilly closed its research center in China?

Why Eli Lilly closed its research center in China?

On September 7th, Eli Lilly, the US Pharma giant, closed its Zhangjiang research center in China, just a month after GlaxoSmithKline (GSK)’s ended its neuroscience unit in Shanghai. Andrew Hodge, the president and general manager of Lilly China, announced the news to the Chinese employees. He stressed that the move is slated to optimize the …

Read Article Read More

Uncategorized A look of the major listed cell immunotherapy companies in China

A look of the major listed cell immunotherapy companies in China

The summer of 2017 is the start of the golden age for cell immunotherapy. Since the end of June, there is no shortage of attention in this red-hot market. On June 29th, Sanpower Group, the Chinese pharma giant, has announced its acquisition of Dendreon with $819 million. The core product of the latter is the …

Read Article Read More

Uncategorized Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies

Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies

On September 21st, Zai Lab, the Chinese biopharma start-up, has officially listed in the United States Nasdaq global market, bagged a total of $150 million. On the same day, its stock rose 55.17%, amount to $27.93 per share. Zai Lab is not the first Chinese biopharmaceutical company which has completed an IPO in the United …

Read Article Read More